R
Arcadia Biosciences, Inc.
RKDACIK 0001469443NasdaqNon-AcceleratedSmaller ReportingCrude Petroleum & Natural GasDelawareFY ends Dec 31
Period
FY 2025
Revenue
$4.86M
Net Income
$-2.34M
Total Assets
—
Equity
—
Shares Out
2.06M
Op. Cash Flow
—
Business
Arcadia Biosciences is a consumer goods company that develops and commercializes branded beverage and agricultural products. The company's primary product is Zola Coconut Water, a branded beverage sourced from Thailand and sold through grocery retailers and foodservice distributors in the U.S. Arcadia previously developed and licensed agronomic wheat traits but has divested its wheat-related intellectual property and commercialization rights as of 2024–2025.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 5 | 5 | 4 | 7 | 7 | |
| Cost of revenues | 3 | 3 | 2 | 6 | 9 | |
| Research and development | 9,000 | 53,000 | 64,000 | 2 | 4 | |
| Gain on sale of intangible assets | −750,000 | −4 | 0 | — | — | |
| Impairment of property and equipment | 0 | 36,000 | 0 | 160,000 | 2 | |
| Change in fair value of contingent consideration | −2 | 0 | — | — | — | |
| Selling, general and administrative | 7 | 10 | 8 | 15 | 23 | |
| Total operating expenses | 7 | 9 | 11 | 21 | 42 | |
| Loss from operations | −3 | −4 | −6 | −14 | −36 | |
| Interest income | 221,000 | 782,000 | 695,000 | 289,000 | −20,000 | |
| Credit loss | −5 | 0 | — | — | — | |
| Other income, net | 2 | 31,000 | 48,000 | 9,000 | 10 | |
| Change in fair value of common stock warrant and option liabilities | 2 | −1 | 7 | 3 | 9 | |
| Net loss from continuing operations before income taxes | −2 | −4 | −5 | −11 | — | |
| Income tax expense | −8,000 | −8,000 | −8,000 | −14,000 | −2,000 | |
| Net loss from continuing operations | −2 | −4 | −5 | −11 | — | |
| Net loss attributable to common stockholders | −2 | −7 | −14 | −15 | −15 | |
| Basic net loss per share attributable to common stockholders from continuing operations | −1.71 | −3.17 | −4.3 | −17.67 | — | |
| Diluted net loss per share attributable to common stockholders from continuing operations | −1.71 | −3.17 | −4.3 | −17.67 | — | |
| Basic net loss per share attributable to common stockholders from discontinued operations | 0 | −2 | −6.99 | −7.98 | — | |
| Diluted net loss per share attributable to common stockholders from discontinued operations | 0 | −2 | −6.99 | −7.98 | — | |
| Net loss per basic share attributable to common stockholders | −1.71 | −5.17 | −11.29 | −25.65 | −27.56 | |
| Net loss per diluted share attributable to common stockholders | −1.71 | −5.17 | −11.29 | −25.65 | −27.56 | |
| Weighted average shares - Basic | 1 | 1 | 1 | 599,389 | 532,016 | |
| Weighted average shares - Diluted | 1 | 1 | 1 | 599,389 | 532,016 | |
| Unrealized gains on available-for-sale securities | 0 | 127,000 | 101,000 | 0 | — | |
| Reclassification adjustment for gains on available-for-sale securities included in net loss | 0 | −228,000 | 0 | — | — | |
| Change in unrealized gains on available-for-sale securities | 0 | −101,000 | 101,000 | — | — | |
| Comprehensive loss | −2 | −7 | −14 | −15 | −15 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 300,000 | 4 | 7 | 21 | 29 | |
| Short-term investments | 4 | 0 | 5 | 0 | — | |
| Accounts receivable and other receivables, net of allowance for credit loss of $559 and $0 as of December 31, 2025 and 2024, respectively | 425,000 | 1 | 506,000 | 1 | 1 | |
| Inventories | 1 | 904,000 | 837,000 | 2 | 4 | |
| Note receivable - current, net of allowance for credit losses (Note 8) | 0 | 2 | 0 | — | — | |
| Prepaid expenses and other current assets | 156,000 | 931,000 | 807,000 | 795,000 | 900,000 | |
| Current assets of discontinued operations - GoodWheat | 0 | 96,000 | 1 | 330,000 | — | |
| Total current assets | 6 | 9 | 15 | 25 | 35 | |
| Property and equipment, net | 8,000 | 41,000 | 70,000 | 680,000 | 2 | |
| Right of use assets | 0 | 137,000 | 792,000 | 2 | 3 | |
| Intangible assets, net | 39,000 | 39,000 | 39,000 | 40,000 | 484,000 | |
| Note receivable - noncurrent, net of allowance for credit losses (Note 8) | 0 | 4 | 0 | — | — | |
| Other noncurrent assets | 143,000 | 92,000 | 164,000 | 165,000 | 180,000 | |
| Total assets | 7 | 14 | 20 | 29 | 44 | |
| Accounts payable and accrued expenses | 2 | 2 | 2 | 3 | 4 | |
| Operating lease liability - current | 0 | 155,000 | 852,000 | 1 | 1 | |
| Total current liabilities | 2 | 3 | 4 | 4 | 5 | |
| Common stock warrant and option liabilities | 347,000 | 3 | 1 | 806,000 | 3 | |
| Other noncurrent liabilities | 0 | 2 | 2 | 2 | 2 | |
| Total liabilities | 2 | 7 | 7 | 8 | 13 | |
| Commitments and contingencies (Note 14) | — | — | — | — | — | |
| Common stock, $0.001 par value -150,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 1,373,120 and 1,364,940 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively. | 65,000 | 65,000 | 65,000 | 65,000 | 63,000 | |
| Additional paid-in capital | 285 | 285 | 285 | 279 | 258 | |
| Accumulated deficit | −281 | −279 | −272 | −258 | −226 | |
| Total stockholders' equity | 4 | 6 | 13 | 21 | 31 | |
| Total liabilities and stockholders equity | 7 | 14 | 20 | 29 | 44 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Change in fair value of contingent consideration | −2 | — | — | — | — | |
| Depreciation | 32,000 | 113,000 | 287,000 | — | — | |
| Lease amortization | 122,000 | 652,000 | 697,000 | 884,000 | 1 | |
| Amortization of note receivable discount | −69,000 | −157,000 | 0 | — | — | |
| Gain on disposal of property and equipment | 0 | −65,000 | −40,000 | — | 23,000 | |
| Gain on receipt of Above Food Ingredients, Inc. common stock | −1 | 0 | — | — | — | |
| Unrealized gain subsequent to receipt of Above Food Ingredients, Inc. common stock | −1 | 0 | — | — | — | |
| Stock-based compensation | 234,000 | 512,000 | 717,000 | 1 | 2 | |
| Credit loss | 5 | 0 | 20,000 | 60,000 | 76,000 | |
| Write-down of inventories | 0 | 154,000 | 444,000 | 3 | 4 | |
| Impairment of property and equipment | 0 | 36,000 | 0 | 530,000 | — | |
| Write-down of non-controlling interest | 0 | 138,000 | 0 | — | — | |
| Accounts receivable and other receivables | 165,000 | −762,000 | 184,000 | 592,000 | −40,000 | |
| Inventories | −308,000 | 550,000 | −2 | 1 | −2 | |
| Prepaid expenses and other current assets | 775,000 | −124,000 | 1,000 | 91,000 | 56,000 | |
| Other noncurrent assets | −50,000 | 72,000 | 2,000 | 16,000 | −158,000 | |
| Accounts payable and accrued expenses | −399,000 | −303,000 | −522,000 | −757,000 | −372,000 | |
| Amounts due to related parties | −30,000 | −29,000 | 10,000 | −16,000 | −16,000 | |
| Other current liabilities | −57,000 | 0 | 0 | 6,000 | 1,000 | |
| Operating lease payments | −122,000 | −850,000 | −764,000 | −932,000 | −1 | |
| Net cash used in operating activities | −5 | −10 | −15 | −14 | −26 | |
| Proceeds from sale of property and equipment | 0 | 334,000 | 115,000 | 920,000 | 19,000 | |
| Proceeds from sale of investments | 0 | 5 | 3 | 0 | — | |
| Proceeds from sale of intangible assets | 750,000 | 4 | 0 | — | — | |
| Cash paid related to sale of GoodWheat | 0 | −2 | 0 | — | — | |
| Purchases of property and equipment | 0 | −16,000 | −5,000 | −72,000 | −1 | |
| Net cash provided by investing activities | 750,000 | 7 | −4 | 1 | 17 | |
| Proceeds from ESPP purchases | 6,000 | 9,000 | 12,000 | 7,000 | — | |
| Net cash provided by financing activities | 6,000 | 9,000 | 6 | 5 | 22 | |
| Net decrease in cash and cash equivalents | −4 | −2 | −14 | −8 | 13 | |
| Right of use assets obtained in exchange for new operating lease liabilities | 0 | 86,000 | 0 | 114,000 | 2 | |
| Note receivable recognized from sale of GoodWheat | 0 | 6 | 0 | — | — | |
| Fair value of Above Food Ingredients, Inc. common stock received | 3 | 0 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Arcadia Biosciences, Inc.'s CIK number?
Arcadia Biosciences, Inc.'s SEC CIK number is 0001469443 (1469443). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Arcadia Biosciences, Inc.'s SEC filings?
All of Arcadia Biosciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Arcadia Biosciences, Inc. last report earnings?
Arcadia Biosciences, Inc. (RKDA) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-223985). This is Arcadia Biosciences, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Arcadia Biosciences, Inc.'s most recent earnings 8-K?
Arcadia Biosciences, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001193125-26-223985. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Arcadia Biosciences, Inc.'s latest earnings 8-K →
Look up any company's CIK number →